First Dose of COVID-19 Vaccine Candidate

The Volunteers were Injected with the First Dose of COVID-19 Vaccine Candidate, Developed by Erciyes University

Erciyes University made a significant progress in novel coronavirus (Covid-19) vaccine studies. The R&D studies of the inactive vaccine candidate which was developed locally and nationally against Covid-19 at Erciyes University Vaccine Research and Development Center (ERAGEM), produced under GMP conditions in Kocak Pharma and supported by the Ministry of Health were completed. After the ethics committee approval for the inactive vaccine candidate and receiving the approval of the Ministry of Health, the Phase 1 trials were initiated by injecting a volunteer with the first dose at Erciyes University Good Clinical Practice and Research Center (IKUM).

The first dose of the vaccine candidate developed against Covid-19 by the academic staff of Erciyes University was administered to Nazif Durna, the first volunteer, at IKUM, which is one of the few Phase 1 licensed centers in our country, completed lots of national and international clinical studies successfully previously and will play an important role in developing other local vaccines in our country.

Nazif Durna, the first volunteer to be injected, said that he was happy to be a volunteer in the vaccine study and also wished to be a hope for people. He thanked the academic staff for their studies.

Prof. Dr. Mustafa Çalış, Rector of Erciyes University, told that pre-clinical studies of the vaccine candidate developed against Covid-19 by ERAGEM were completed and they planned to complete the Phase 1 trials by early January. Rector Prof. Dr. Çalış continued his words: “Today, the first volunteer was injected with the vaccine candidate the pre-clinical studies of which we completed. Therefore, we proceeded to the Phase 1 trial in the vaccine study. The Phase 1 trial will last approximately for two months. Hopefully, we are planning to complete it by early January. If the Phase 1 trials become successful, we are planning to proceed with other Phase trials. I hope that the vaccine candidate developed by our university and other vaccines developed by the other vaccine centers in our country will be the national vaccines against Covid-19 for our citizens. I would like to thank everyone for their efforts.”

Rector Prof. Dr. Çalış also added that IKUM is one of the few centers in Turkey where Phase 1 trials of other developed Covid-19 vaccines would be fulfilled.

This inactive vaccine candidate will be administered to 44 volunteers in total who are healthy individuals between the ages of 18-55 and have not undergone Covid-19 before.

The Phase 1 trial of the vaccine candidate which will be administered to the volunteers twice with an interval of 3 weeks is planned to be completed on January 5, 2021. In the event of successful completion of the Phase 1 trial of the inactive vaccine candidate, the Phase 2 trials will be initiated in January 2021.

Under Project, internship offers sent to 14,115 students with participation of 231 employers.

Article of METU University in Nature